Brokers Issue Forecasts for INBX Q3 Earnings

Inhibrx Biosciences, Inc. (NASDAQ:INBX) – Stock analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for Inhibrx Biosciences in a report released on Monday, August 24th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($2.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $245.00 target price on the stock. The consensus estimate for Inhibrx Biosciences’ current full-year earnings is ($10.88) per share. HC Wainwright also issued estimates for Inhibrx Biosciences’ Q4 2026 earnings at ($2.30) EPS, FY2026 earnings at ($8.93) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.15) EPS, Q3 2027 earnings at ($2.08) EPS, Q4 2027 earnings at ($2.02) EPS and FY2027 earnings at ($8.47) EPS.

Inhibrx Biosciences (NASDAQ:INBX) last posted its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.28) by ($0.06).

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $197.50.

Inhibrx Biosciences Stock Up 16.9%

Shares of NASDAQ:INBX opened at $122.72 on Wednesday. The firm has a market capitalization of $1.81 billion, a PE ratio of -13.82 and a beta of 3.51. Inhibrx Biosciences has a 1 year low of $24.27 and a 1 year high of $155.29. The company has a debt-to-equity ratio of 12.58, a current ratio of 5.07 and a quick ratio of 5.07. The firm’s 50-day moving average is $92.45 and its two-hundred day moving average is $89.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd purchased a new stake in shares of Inhibrx Biosciences in the 4th quarter valued at approximately $27,000. Strs Ohio acquired a new stake in shares of Inhibrx Biosciences in the 1st quarter valued at $27,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Inhibrx Biosciences during the 3rd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Inhibrx Biosciences by 26.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock worth $56,000 after purchasing an additional 147 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Inhibrx Biosciences by 71.9% during the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after purchasing an additional 789 shares in the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences News Roundup

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $245 price target, implying approximately 99.6% upside from the referenced $122.72 price. The bullish target appears to be the primary catalyst supporting the stock’s increase. HC Wainwright Begins Coverage on Inhibrx Biosciences
• Positive Sentiment: HC Wainwright projects 2026 EPS of -$8.93 and 2027 EPS of -$8.47, both less negative than the current full-year consensus estimate of -$10.88. The forecasts suggest expectations for reduced losses over time, although the company remains unprofitable.
• Neutral Sentiment: The firm estimates quarterly losses of $2.14 per share in Q3 2026 and $2.30 in Q4 2026, followed by $2.22, $2.15, $2.08 and $2.02 in the four quarters of 2027. These projections provide a forward earnings framework but do not indicate near-term profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 25, unchanged from the prior reported period. This indicates no meaningful short-selling pressure in the available data, though the figure may reflect incomplete or anomalous reporting.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.